Assignee
ZOGENIX INTERNATIONAL LTD
GB·21 granted patents·34 pending applications·166 citations·filing 2015–2024
Top patents by PatentIndex Score
55 records- 0198US11634377B2Fenfluramine compositions and methods of preparing the sameZOGENIX INTERNATIONAL LTD·Filed 2021·Granted Apr 25, 2023·5 cites·16 claims
- 0298US11325882B2Metabolism resistant fenfluramine analogs and methods of using the sameZOGENIX INTERNATIONAL LTD·Filed 2020·Granted May 10, 2022·4 cites·3 claims
- 0398US11040018B2Formulation for inhibiting formation of 5-HT2B agonists and methods of using sameZOGENIX INTERNATIONAL LTD·Filed 2020·Granted Jun 22, 2021·10 cites·9 claims
- 0497US11673852B2Metabolism resistant fenfluramine analogs and methods of using the sameZOGENIX INTERNATIONAL LTD·Filed 2022·Granted Jun 13, 2023·2 cites·4 claims
- 0597US11406606B2Formulation for inhibiting formation of 5-HT2B agonists and methods of using sameZOGENIX INTERNATIONAL LTD·Filed 2022·Granted Aug 9, 2022·5 cites·22 claims
- 0696US11759440B2Formulation for inhibiting formation of 5-HT2B agonists and methods of using sameZOGENIX INTERNATIONAL LTD·Filed 2021·Granted Sep 19, 2023·3 cites·10 claims
- 0796US11612574B2Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ZOGENIX INTERNATIONAL LTD·Filed 2021·Granted Mar 28, 2023·4 cites·20 claims
- 0895US10351510B2Fenfluramine compositions and methods of preparing the sameZOGENIX INTERNATIONAL LTD·Filed 2018·Granted Jul 16, 2019·16 cites·18 claims
- 0995US10351509B2Fenfluramine compositions and methods of preparing the sameZOGENIX INTERNATIONAL LTD·Filed 2016·Granted Jul 16, 2019·16 cites·22 claims
- 1094US11786487B2Formulation for inhibiting formation of 5-HT2B agonists and methods of using sameZOGENIX INTERNATIONAL LTD·Filed 2021·Granted Oct 17, 2023·2 cites·9 claims
- 1194US11458111B2Ketogenic diet compatible fenfluramine formulationZOGENIX INTERNATIONAL LTD·Filed 2020·Granted Oct 4, 2022·5 cites·26 claims
- 1294US10689324B2Metabolism resistant fenfluramine analogs and methods of using the sameZOGENIX INTERNATIONAL LTD·Filed 2016·Granted Jun 23, 2020·11 cites·3 claims
- 1394US10603290B2Formulation for inhibiting formation of 5-HT2B agonists and methods of using sameZOGENIX INTERNATIONAL LTD·Filed 2018·Granted Mar 31, 2020·10 cites·10 claims
- 1493US10947183B2Fenfluramine compositions and methods of preparing the sameZOGENIX INTERNATIONAL LTD·Filed 2019·Granted Mar 16, 2021·10 cites·33 claims
- 1590US11571397B2Compositions and methods for treating seizure-induced sudden deathZOGENIX INTERNATIONAL LTD·Filed 2018·Granted Feb 7, 2023·6 cites·21 claims
- 1690US10950331B2Control system for control of distribution of medicationZOGENIX INTERNATIONAL LTD·Filed 2018·Granted Mar 16, 2021·11 cites·10 claims
- 1790US10682317B2Ketogenic diet compatible fenfluramine formulationZOGENIX INTERNATIONAL LTD·Filed 2018·Granted Jun 16, 2020·10 cites·11 claims
- 1890US10452815B2Control system for control of distribution of medicationZOGENIX INTERNATIONAL LTD·Filed 2015·Granted Oct 22, 2019·13 cites·9 claims
- 1989US10952976B2Compositions and methods for treating respiratory depression with fenfluramineZOGENIX INTERNATIONAL LTD·Filed 2019·Granted Mar 23, 2021·11 cites·13 claims
- 2089US10517841B1Compositions and methods for treating respiratory depression with fenfluramineZOGENIX INTERNATIONAL LTD·Filed 2019·Granted Dec 31, 2019·12 cites·22 claims
- 2184US2024245631A1Methods of treating lennox-gastaut syndrome using fenfluramineZOGENIX INTERNATIONAL LTD·Filed 2024·Application pending·0 cites
- 2284US2024238222A1Methods of treating lennox-gastaut syndrome using fenfluramineZOGENIX INTERNATIONAL LTD·Filed 2024·Application pending·0 cites
- 2376US2022370381A1Compositions and methods for treating seizure disordersZOGENIX INTERNATIONAL LTD·Filed 2022·Application pending·0 cites
- 2475US2023076320A1Norfenfluramine to treat dravet syndromeZOGENIX INTERNATIONAL LTD·Filed 2022·Application pending·0 cites
- 2573US2019091174A1Method of reducing seizure type experienced by a dravet patientZOGENIX INTERNATIONAL LTD·Filed 2018·Application pending·0 cites
- 2671US2019091176A1Method of treating selected patient population experiencing dravet syndromeZOGENIX INTERNATIONAL LTD·Filed 2018·Application pending·0 cites
- 2771US2020276136A1Method of treating selected patient population experiencing dravet syndromeZOGENIX INTERNATIONAL LTD·Filed 2020·Application pending·0 cites
- 2870US2023093150A1Changing cognitive function with fenfluramineZOGENIX INTERNATIONAL LTD·Filed 2022·Application pending·0 cites
- 2968US2024299317A1Fenfluramine for Treatment of Conditions Associated with Spreading DepolarizationZOGENIX INTERNATIONAL LTD·Filed 2024·Application pending·0 cites
- 3068US2025032431A1Methods of treating rett syndrome using fenfluramineZOGENIX INTERNATIONAL LTD·Filed 2024·Application pending·0 cites
- 3167US2019091173A1Method of increasing time between convulsive seizuresZOGENIX INTERNATIONAL LTD·Filed 2018·Application pending·0 cites
- 3267US2020297665A1Compositions and methods for treating seizure disordersZOGENIX INTERNATIONAL LTD·Filed 2020·Application pending·0 cites
- 3367US2019125697A1Method of reduction in convulsive seizure frequencyZOGENIX INTERNATIONAL LTD·Filed 2018·Application pending·0 cites
- 3467US2020253895A1Methods of treating lennox-gastaut syndrome using fenfluramineZOGENIX INTERNATIONAL LTD·Filed 2020·Application pending·0 cites
- 3566US2022226262A1Methods of treating doose syndrome using fenfluramineZOGENIX INTERNATIONAL LTD·Filed 2022·Application pending·0 cites
- 3666US2023165810A1Fenfluramine for treatment of conditions associated with spreading depolarizationZOGENIX INTERNATIONAL LTD·Filed 2022·Application pending·0 cites
- 3766US2018092864A1Compositions and methods for treating seizure disordersZOGENIX INTERNATIONAL LTD·Filed 2017·Application pending·0 cites
- 3866US2021158920A1Control system for control of distribution of medicationZOGENIX INTERNATIONAL LTD·Filed 2021·Application pending·0 cites
- 3965US2019091177A1Method of treating selected patient population experiencing dravet syndromeZOGENIX INTERNATIONAL LTD·Filed 2018·Application pending·0 cites
- 4064US2019091175A1Method of reduction medication in treating dravet syndromeZOGENIX INTERNATIONAL LTD·Filed 2018·Application pending·0 cites
- 4163US12144787B2Method of treating patients with a mutation in cyclin-dependent kinase-like 5 (CDKL5)ZOGENIX INTERNATIONAL LTD·Filed 2019·Granted Nov 19, 2024·0 cites·17 claims
- 4263US2018055789A1Formulation for inhibiting formation of 5-ht2b agonists and methods of using sameZOGENIX INTERNATIONAL LTD·Filed 2017·Application pending·0 cites
- 4360US2020170965A1Methods of treating doose syndrome using fenfluramineZOGENIX INTERNATIONAL LTD·Filed 2018·Application pending·0 cites
- 4457US2020306210A1Changing cognitive function with fenfluramineZOGENIX INTERNATIONAL LTD·Filed 2019·Application pending·0 cites
- 4554US2019091179A1Congnitive function with fenfluramineZOGENIX INTERNATIONAL LTD·Filed 2018·Application pending·0 cites
- 4654US2018325909A1Combination treatment of specific forms of epilepsyZOGENIX INTERNATIONAL LTD·Filed 2018·Application pending·0 cites
- 4754US2022193082A1Combination treatment of specific forms of epilepsyZOGENIX INTERNATIONAL LTD·Filed 2022·Application pending·0 cites
- 4853US2021113495A1Method of treating epilepsy or epileptic encephalopathy with fenfluramine in patients without pulmonary hypertensionZOGENIX INTERNATIONAL LTD·Filed 2019·Application pending·0 cites
- 4952US2021401776A1Method of treating refractory epilepsy syndromes using fenfluramine enantiomersZOGENIX INTERNATIONAL LTD·Filed 2019·Application pending·0 cites
- 5051US2019083425A1Formulation for inhibiting formation of 5-ht2b agonists and methods of using sameZOGENIX INTERNATIONAL LTD·Filed 2018·Application pending·0 cites
Showing the top 50 of 55 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when ZOGENIX INTERNATIONAL LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →